TY - JOUR
T1 - Drug-targeting strategies for prostate cancer
AU - Ast, Gil
PY - 2003
Y1 - 2003
N2 - Prostate cancer is the most frequently diagnosed cancer in North American men and accounts for 10% of cancer-related deaths in men. Despite advances in early detection and aggressive treatment of early disease, the overall mortality rate has not appear to have fallen, indicating that the current therapies are not beneficial for life expectancy and new strategies are required. Prostate cancer is a dynamic evolving process that develops in distinct steps, with each step liable to additional genetic hits that change the cancer cell phenotype and alter the patterns of gene expression. The molecular events in prostate cancer are beginning to be understood, including altered expression of tumor suppressor genes, pro- and anti-apoptotic genes, and oncogenes associated with the progression of the disease; and specific genes that are expressed predominantly or exclusively in prostate cells, prostate cancer cells, and prostate metastasis cells. These latter genes on the level of DNA, RNA and protein products are the targets of several new approaches to prostate cancer therapy and are the focus of this review.
AB - Prostate cancer is the most frequently diagnosed cancer in North American men and accounts for 10% of cancer-related deaths in men. Despite advances in early detection and aggressive treatment of early disease, the overall mortality rate has not appear to have fallen, indicating that the current therapies are not beneficial for life expectancy and new strategies are required. Prostate cancer is a dynamic evolving process that develops in distinct steps, with each step liable to additional genetic hits that change the cancer cell phenotype and alter the patterns of gene expression. The molecular events in prostate cancer are beginning to be understood, including altered expression of tumor suppressor genes, pro- and anti-apoptotic genes, and oncogenes associated with the progression of the disease; and specific genes that are expressed predominantly or exclusively in prostate cells, prostate cancer cells, and prostate metastasis cells. These latter genes on the level of DNA, RNA and protein products are the targets of several new approaches to prostate cancer therapy and are the focus of this review.
KW - Androgen
KW - Antisense
KW - Cancer
KW - Gene therapy
KW - Peptidase
KW - Prodrug
KW - Prostate
KW - Prostate specific antigen (PSA)
UR - http://www.scopus.com/inward/record.url?scp=0037241958&partnerID=8YFLogxK
U2 - 10.2174/1381612033391603
DO - 10.2174/1381612033391603
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 12570809
AN - SCOPUS:0037241958
SN - 1381-6128
VL - 9
SP - 455
EP - 466
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 6
ER -